Lynne Brum - Yield10 Bioscience Vice President - Planning and Communications
| YTEN Stock | USD 0.01 0.00 0.00% |
President
Ms. Lynne H. Brum is a Vice President Planning and Communications of the Company. Ms. Brum has served as vice president, marketing and corporate communications, of the Company since November, 2011. Prior to joining Metabolix, in 2010 to 2011 she was a communications consultant and served in various roles including as a freelance project director for Seidler Bernstein Inc. Ms. Brum served from 2007 to 2009 as an executive vice president at Porter Novelli Life Sciences, a subsidiary of global PR firm, Porter Novelli International. Prior to that, Ms. Brum was responsible for corporate communications, investor relations and brand management for Vertex Pharmaceuticals, Inc. from 1994 to 2007 in various positions, including vice president of strategic communications. Ms. Brum was also a vice president at Feinstein Kean Healthcare and was part of the communications team at Biogen, Inc. since 2016.
| Age | 61 |
| Tenure | 9 years |
| Phone | (617) 583-1700 |
| Web | https://www.yield10bio.com |
Lynne Brum Latest Insider Activity
Tracking and analyzing the buying and selling activities of Lynne Brum against Yield10 Bioscience stock is an integral part of due diligence when investing in Yield10 Bioscience. Lynne Brum insider activity provides valuable insight into whether Yield10 Bioscience is net buyers or sellers over its current business cycle. Note, Yield10 Bioscience insiders must abide by specific rules, including filing SEC forms every time they buy or sell Yield10 Bioscience'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Lynne Brum over a year ago Acquisition by Lynne Brum of 100000 shares of Yield10 Bioscience at 0.3 subject to Rule 16b-3 |
Yield10 Bioscience Management Efficiency
The company has return on total asset (ROA) of (1.7811) % which means that it has lost $1.7811 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.0809) %, meaning that it created substantial loss on money invested by shareholders. Yield10 Bioscience's management efficiency ratios could be used to measure how well Yield10 Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Yield10 Bioscience currently holds 3.21 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Yield10 Bioscience has a current ratio of 6.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Yield10 Bioscience's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Susan Menzel | CF Industries Holdings | 60 | |
| Miri Mishor | ICL Israel Chemicals | 61 | |
| Richard McLellan | The Mosaic | 63 | |
| Pedro Farah | Nutrien | N/A | |
| Michael Webb | Nutrien | N/A | |
| Robert Gilbane | American Vanguard | 74 | |
| Mark McDonald | Intrepid Potash | 54 | |
| Andrew Sandifer | FMC Corporation | 55 | |
| Nitzan Moshe | ICL Israel Chemicals | 53 | |
| Bert Frost | CF Industries Holdings | 60 | |
| Gregory Friedman | Corteva | 52 | |
| Philip Brown | ICL Israel Chemicals | 55 | |
| Ron Baruchi | ICL Israel Chemicals | N/A | |
| Leslie ODonoghue | Nutrien | 55 | |
| Ido Lilian | ICL Israel Chemicals | 61 | |
| Sam Eathington | Corteva | 52 | |
| Terje Knutsen | Yara International ASA | 61 | |
| Ivan Smith | Scotts Miracle Gro | 51 | |
| Noam Goldstein | ICL Israel Chemicals | 63 | |
| David Anderson | Corteva | 71 | |
| Lars Rosaeg | Yara International ASA | 41 | |
Management Performance
| Return On Equity | -15.08 | |||
| Return On Asset | -1.78 |
Yield10 Bioscience Leadership Team
Elected by the shareholders, the Yield10 Bioscience's board of directors comprises two types of representatives: Yield10 Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Yield10. The board's role is to monitor Yield10 Bioscience's management team and ensure that shareholders' interests are well served. Yield10 Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Yield10 Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lynne Brum, Vice President - Planning and Communications | ||
| Nicholas Renegar, Director Operations | ||
| Kristi Snell, Chief Science Officer, Vice President - Research | ||
| Charles CPA, Chief Finance | ||
| Charles Haaser, Chief Accounting Officer, Vice President - Finance | ||
| ScD Sinskey, CoFounder Director | ||
| Oliver Peoples, President CEO, Director |
Yield10 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Yield10 Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.08 | |||
| Return On Asset | -1.78 | |||
| Operating Margin | (7.12) % | |||
| Current Valuation | 2.07 M | |||
| Shares Outstanding | 692.68 K | |||
| Shares Owned By Insiders | 17.54 % | |||
| Shares Owned By Institutions | 0.03 % | |||
| Number Of Shares Shorted | 60.7 K | |||
| Price To Earning | (3.19) X | |||
| Price To Book | 11.23 X |
Pair Trading with Yield10 Bioscience
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Yield10 Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Yield10 Bioscience will appreciate offsetting losses from the drop in the long position's value.Moving against Yield10 Stock
| 0.31 | VZ | Verizon Communications Aggressive Push | PairCorr |
The ability to find closely correlated positions to Yield10 Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Yield10 Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Yield10 Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Yield10 Bioscience to buy it.
The correlation of Yield10 Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Yield10 Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Yield10 Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Yield10 Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Yield10 Bioscience. If investors know Yield10 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Yield10 Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Yield10 Bioscience is measured differently than its book value, which is the value of Yield10 that is recorded on the company's balance sheet. Investors also form their own opinion of Yield10 Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Yield10 Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Yield10 Bioscience's market value can be influenced by many factors that don't directly affect Yield10 Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Yield10 Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Yield10 Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Yield10 Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.